SEARCH

SEARCH BY CITATION

References

  • Ackermann, M.R., Derscheid, R. & Roth, J.A. (2010) Innate immunology of bovine respiratory disease. Veterinary Clinics of North America: Food Animal Practice, 26, 215228.
  • Aliabadi, F.S. & Lees, P. (2002) Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics, 25, 161174.
  • Blondeau, J.M., Zhao, X., Hansen, G. & Drlica, K. (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 45, 433438.
  • Campion, J.J., McNamara, P.J. & Evans, M.E. (2004) Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrobial Agents and Chemotherapy, 48, 47334744.
  • Cardenas, M., Barbé, J., Llagostera, M., Miro, E., Navarro, F., Mirelis, B., Prats, G. & Badiola, I. (2001) Quinolone resistance-determining regions of gyrA and parC in Pasteurella multocida strains with different levels of nalidixic acid resistance. Antimicrobial Agents and Chemotherapy, 45, 990991.
  • Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H. & Chavanet, P. (2004) In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. Journal of Antimicrobial Chemotherapy, 54, 640647.
  • Cui, J., Liu, Y., Wang, R., Tong, W., Drlica, K. & Zhao, X. (2006) The mutant selection window in rabbits infected with Staphylococcus aureus. Journal of Infectious Diseases, 194, 16011608.
  • Dong, Y., Zhao, X., Domagala, J. & Drlica, K. (1999) Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 43, 17561758.
  • Eagle, H. & Musselman, A.D. (1948) The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. The Journal of Experimental Medicine, 88, 99131.
  • EMEA (2002) Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances. EMEA/CVMP/627/01-FINAL. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004492.pdf. Accessed 10 November 2011.
  • Ferran, A., Dupouy, V., Toutain, P.L. & Bousquet-Mélou, A. (2007) Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin. Antimicrobial Agents and Chemotherapy, 51, 41634166.
  • Ferran, A.A., Kesteman, A.S., Toutain, P.L. & Bousquet-Mélou, A. (2009) Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model. Antimicrobial Agents and Chemotherapy , 53, 33843390.
  • Ferran, A., Toutain, P.L. & Bousquet-Mélou, A. (2011) Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection. Veterinary Microbiology, 148, 292297.
  • Firsov, A.A., Vostrov, S.N., Lubenko, I.Y., Drlica, K., Portnoy, Y.A. & Zinner, S.H. (2003) In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 47, 16041613.
  • Forbes, A.B., Ramage, C., Sales, J., Baggott, D. & Donachie, W. (2011) Determination of the duration of antibacterial efficacy following administration of Gamithromycin using a bovine Mannheimia haemolytica challenge model. Antimicrobial Agents and Chemotherapy, 55, 831835.
  • Gebru, E., Choi, M.J., Lee, S.J., Damte, D. & Park, S.C. (2011) Mutant prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin. Journal of Medical Microbiology, 60, 15121522.
  • Ismail, M. & El-Kattan, Y.A. (2007) Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves. Research in Veterinary Science, 82, 398404.
  • Kesteman, A.S., Ferran, A.A., Perrin-Guyomard, A., Laurentie, M., Sanders, P., Toutain, P.L. & Bousquet-Mélou, A. (2009) Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model. Antimicrobial Agents and Chemotherapy, 53, 47404748.
  • Kesteman, A.S., Perrin-Guyomard, A., Laurentie, M., Sanders, P., Toutain, P.L. & Bousquet-Mélou, A. (2010) Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats. Antimicrobial Agents and Chemotherapy, 54, 29602964.
  • Kroemer, S., Galland, S., Guérin-Faublé, V., Giboin, H. & Woehrlé-Fontaine, F. (2011) Survey of marbofloxacin susceptibility of bacteria isolated from bovine respiratory disease and mastitis in Europe. Veterinary Record, doi: 10.1136/vr.100037.
  • Lewis, K. (2010) Persister cells. Annual Review of Microbiology, 13, 357372.
  • Mann, S., Siler, J.D., Jordan, D. & Warnick, L.D. (2011) Antimicrobial susceptibility of fecal Escherichia coli isolates in dairy cows following systemic treatment with ceftiofur or penicillin. Foodborne Pathogens and Disease, 8, 861867.
  • Martinez, M., McDermott, P. & Walker, R. (2006) Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Veterinary Journal, 172, 1028.
  • Meunier, D., Acar, J.F., Martel, J.L., Kroemer, S. & Vallé, M. (2004) Seven years survey of susceptibility to marbofloxacin of bovine pathogenic strains from eight European countries. International Journal of Antimicrobial Agents, 24, 268278.
  • Mouton, J.W., Dudley, M.N., Cars, O., Derendorf, H. & Drusano, G.L. (2005) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. Journal of Antimicrobial Chemotherapy, 55, 601607.
  • Olliver, A., Vallé, M., Chaslus-Dancla, E. & Cloeckaert, A. (2005) Overexpression of the multidrug efflux operon acrEF by insertional activation with IS1 or IS10 elements in Salmonella enterica serovar typhimurium DT204 acrB mutants selected with fluoroquinolones. Antimicrobial Agents and Chemotherapy, 49, 289301.
  • Pellet, T., Gicquel-Bruneau, M., Sanders, P. & Laurentie, M. (2006) Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli. Research in Veterinary Science, 80, 324335.
  • Schentag, J.J. (1999) Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. Journal of Chemotherapy, 11, 426439.
  • Schneider, M., Thomas, V., Boisrame, B. & Deleforge, J. (1996) Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. Journal of Veterinary Pharmacology and Therapeutics, 19, 5661.
  • Sidhu, P.K., Landoni, M.F., Aliabadi, M.H., Toutain, P.L. & Lees, P. (2011) Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in calves. Journal of Veterinary Pharmacology and Therapeutics, 34, 376387.
  • Smith, H.J., Nichol, K.A., Hoban, D.J. & Zhanel, G.G. (2003) Stretching the mutant prevention concentration (MPC) beyond its limits. Journal of Antimicrobial Chemotherapy, 51, 13231325.
  • Thomas, E., Caldow, G.L., Borell, D. & Davot, J.L. (2001) A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of bovine respiratory disease. Journal of Veterinary Pharmacology and Therapeutics, 24, 353358.
  • Toutain, P.L., del Castillo, J.R. & Bousquet-Mélou, A. (2002) The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science, 73, 105114.
  • Van Bambeke, F., Michot, J.M., Van Eldere, J. & Tulkens, P.M. (2005) Quinolones in 2005: an update. Clinical Microbiology and Infection, 11, 256280.
  • Wolfson, J.S. & Hooper, D.C. (1985) The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy, 28, 581586.
  • Zhao, X. & Drlica, K. (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clinical Infectious Diseases, 33S, 147156.
  • Zhao, X. & Drlica, K. (2008) A unified anti-mutant dosing strategy. Journal of Antimicrobial Chemotherapy, 62, 434436.